» Articles » PMID: 36232716

Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α-Synucleinopathy Animal Model

Abstract

The α-synucleinopathies constitute a subset of neurodegenerative disorders, of which Parkinson's disease (PD) is the most common worldwide, characterized by the accumulation of misfolded α-synuclein in the cytoplasm of neurons, which spreads in a prion-like manner to anatomically interconnected brain areas. However, it is not clear how α-synucleinopathy triggers neurodegeneration. We recently developed a rat model through a single intranigral administration of the neurotoxic β-sitosterol β-D-glucoside (BSSG), which produces α-synucleinopathy. In this model, we aimed to evaluate the temporal pattern of levels in oxidative and nitrosative stress and mitochondrial complex I (CI) dysfunction and how these biochemical parameters are associated with neurodegeneration in different brain areas with α-synucleinopathy (, the striatum, in the hippocampus and the olfactory bulb, where α-syn aggregation spreads). Interestingly, an increase in oxidative stress and mitochondrial CI dysfunction accompanied neurodegeneration in those brain regions. Furthermore, in silico analysis suggests a high-affinity binding site for BSSG with peroxisome proliferator-activated receptors (PPAR) alpha (PPAR-α) and gamma (PPAR-γ). These findings will contribute to elucidating the pathophysiological mechanisms associated with α-synucleinopathies and lead to the identification of new early biomarkers and therapeutic targets.

Citing Articles

Natural Compounds That Activate the KEAP1/Nrf2 Signaling Pathway as Potential New Drugs in the Treatment of Idiopathic Parkinson's Disease.

Huenchuguala S, Segura-Aguilar J Antioxidants (Basel). 2024; 13(9).

PMID: 39334784 PMC: 11428591. DOI: 10.3390/antiox13091125.


Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model.

Huenchuguala S, Segura-Aguilar J Biomolecules. 2024; 14(6).

PMID: 38927076 PMC: 11201619. DOI: 10.3390/biom14060673.


Neurodegenerative Diseases: Unraveling the Heterogeneity of Astrocytes.

Santiago-Balmaseda A, Aguirre-Orozco A, Valenzuela-Arzeta I, Villegas-Rojas M, Perez-Segura I, Jimenez-Barrios N Cells. 2024; 13(11.

PMID: 38891053 PMC: 11172252. DOI: 10.3390/cells13110921.


Rotenone-induced PINK1/Parkin-mediated mitophagy: establishing a silkworm model for Parkinson's disease potential.

Zhang H, Yang J, Guo Y, Lu P, Gong X, Chen K Front Mol Neurosci. 2024; 17:1359294.

PMID: 38706874 PMC: 11066238. DOI: 10.3389/fnmol.2024.1359294.


Short-term hyperoxia-induced functional and morphological changes in rat hippocampus.

Hencz A, Magony A, Thomas C, Kovacs K, Szilagyi G, Pal J Front Cell Neurosci. 2024; 18:1376577.

PMID: 38686017 PMC: 11057248. DOI: 10.3389/fncel.2024.1376577.


References
1.
Schildknecht S, Gerding H, Karreman C, Drescher M, Lashuel H, Outeiro T . Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem. 2013; 125(4):491-511. DOI: 10.1111/jnc.12226. View

2.
Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee G . Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021; 373(6557):871-876. PMC: 7612213. DOI: 10.1126/science.abj8754. View

3.
Choi M, Gandhi S . Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases. FEBS J. 2018; 285(19):3631-3644. DOI: 10.1111/febs.14587. View

4.
Gfeller D, Michielin O, Zoete V . Shaping the interaction landscape of bioactive molecules. Bioinformatics. 2013; 29(23):3073-9. DOI: 10.1093/bioinformatics/btt540. View

5.
Balestrino R, Schapira A . Parkinson disease. Eur J Neurol. 2019; 27(1):27-42. DOI: 10.1111/ene.14108. View